Kooperativer Bibliotheksverbund

UID:

Format: 1 Online-Ressource (XVII, 320 p. 54 illus., 13 illus. in color).

Edition: 2nd ed. 2023

ISBN: 978-3-031-26090-2

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26089-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26091-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26092-6

Language: English

DOI: 10.1007/978-3-031-26090-2

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XVII, 320 p. 54 illus., 13 illus. in color).

Edition: 2nd ed. 2023

ISBN: 978-3-031-26090-2

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26089-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26091-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26092-6

Language: English

DOI: 10.1007/978-3-031-26090-2

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XVII, 320 p. 54 illus., 13 illus. in color).

Edition: 2nd ed. 2023

ISBN: 978-3-031-26090-2

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26089-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26091-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26092-6

Language: English

DOI: 10.1007/978-3-031-26090-2

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XVII, 320 p. 54 illus., 13 illus. in color)

Edition: 2nd ed. 2023

ISBN: 9783031260902

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26089-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26091-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-26092-6

Language: English

DOI: 10.1007/978-3-031-26090-2

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (x, 170 Seiten) , 44 Illustrationen, 40 in Farbe

ISBN: 9783031458576

Series Statement: Lecture notes in computer science 14293

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-45856-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-031-45858-3

Language: English

Subjects: Computer Science

Keywords: Maschinelles Lernen ; Anwendungssoftware ; Optische Datenverarbeitung ; Konferenzschrift

DOI: 10.1007/978-3-031-45857-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (294 pages).

Edition: First edition.

ISBN: 0-12-812738-4

Series Statement: Cancer sensitizing agents for chemotherapy ; Volume 4

Note: Front Cover -- Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy -- Copyright -- Contents -- Contributors -- About the Editors -- A: Certifications, Honors, Awards, and Other Recognitions -- Research Interests -- About the Series Editor -- Aims and Scope for Series ``Cancer Sensitizing Agents for Chemotherapy´´ -- Preface -- Chapter 1: EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Introduction -- Tyrosine Kinases: Targeting the EGFR and HER2 Receptors -- Resistance to Chemotherapy -- EGFR and HER2 Inhibitors as Sensitizing Agents to Chemotherapy -- Gefitinib -- Erlotinib -- Lapatinib -- Afatinib -- Pelitinib -- Osimertinib -- Conclusion -- Acknowledgments -- References -- Chapter 2: BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Introduction -- BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Imatinib as Sensitizing Agent for Cancer Chemotherapy -- Nilotinib as a Sensitizing Agent for Cancer Chemotherapy -- Dasatinib as a Sensitizing Agent for Cancer Chemotherapy -- Ponatinib as a Sensitizing Agent for Cancer Chemotherapy -- Bosutinib as a Sensitizing Agent for Cancer Chemotherapy -- Bafetinib as a Sensitizing Agent for Cancer Chemotherapy -- Conclusions and Perspectives -- Acknowledgment -- References -- Chapter 3: VEGFR Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Introduction -- Development of chemotherapeutic Agents -- Tumor Angiogenesis and Tumor Angiogenesis Inhibitors (TAIs) -- Tumor Angiogenesis and VEGF/VEGFR Signaling Pathway -- The Development of TAIs -- Bevacizumab -- Ramucirumab -- Sorafenib -- Other TAIs -- Conclusions -- Acknowledgments -- References -- Chapter 4: ALK Tyrosine Kinase Inhibitors in Drug Sensitization -- Introduction -- ALK Signaling Pathway -- ALK TKIs in Reversing Multidrug Resistance -- Crizotinib -- Ceritinib. , Alectinib -- Lorlatinib -- Perspective -- Acknowledgments -- References -- Chapter 5: STAT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Introduction -- STAT3 Inhibitors -- STAT3-DNA-Binding Domain Inhibitors -- STAT3 SH2 Domain Inhibitors -- Peptides -- Small Molecules -- Nature Products -- Conclusion -- Acknowledgments -- References -- Further Reading -- Chapter 6: FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- FLT3 Mutations in Acute Myeloid Leukemia -- FLT3 Mutations in Other Malignancies -- FLT3-ITD and Drug Resistance -- FLT3 Inhibitors -- First- and Second-Generation FLT3 Inhibitors -- Type I and Type II FLT3 Inhibitors -- Reversal of Drug Resistance by FLT3 Inhibition -- Sequence Dependence of Effects of FLT3 Inhibitor on Chemotherapy Response of Cells With FLT3-ITD -- FLT3 Inhibitors-Current Status -- Role of Off-Target Effects in Chemosensitization by FLT3 Inhibitors -- Drug Transport Proteins in AML -- FLT3-ITD and Expression of Drug Transport Proteins -- Tyrosine Kinase Inhibitor Effects on Drug Transport Proteins -- FLT3 Inhibitor Effects on Drug Transport Proteins -- Midostaurin -- Sunitinib -- Sorafenib -- Ponatinib -- Ibrutinib -- Crenolanib -- Gilteritinib -- Quizartinib -- Conclusions -- Acknowledgments -- References -- Chapter 7: Collagen Signaling in Cancer -- Introduction -- Collagen Types -- Collagen Structure -- Collagens in Normal Physiology and Tumorigenesis -- Collagen Expression in Pancreatic Ductal Adenocarcinoma -- Collagen Function in the PDA -- Collagen Receptors -- DDRs -- Regulation of DDR1 Signaling by Secreted Protein Acidic and Rich in Cysteine -- DDR as a Therapeutic Target -- DDR Inhibitors -- Conclusion -- Acknowledgment -- References -- Chapter 8: Bruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Introduction. , BTK and BCR Signaling Pathway -- BTK Inhibitors -- Mechanisms of MDR -- BTK Inhibitors in Sensitization of Resistance to Various Chemotherapy Drugs -- BTK Inhibitors Sensitize Cancer Cells Resistant to Paclitaxel -- BTK Inhibitors Sensitize Cancer Cells Resistant to Cisplatin -- BTK Inhibitors Sensitize Cancer Cells Resistant to Doxorubicin -- BTK Inhibitors Sensitize Cancer Cells Resistant to Proteasome Inhibitors -- BTK Inhibitors Sensitize Cancer Cells Resistant to Bcl-2 Antagonists -- BTK Inhibitors Sensitize Cancer Cells Resistant to HDAC Inhibitors -- Discussion -- Conclusions -- Acknowledgment -- References -- Chapter 9: CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Introduction -- CDKs and Their Regulation of Cell Cycle -- Mechanism of Chemo Sensitization Mediated by CDK4/6 -- CDK4 and 6 Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- First-Generation CDK Inhibitors -- Alvocidib (Flavopiridol) -- UCN-01 (7-Hydroxystaurosporine) -- Seliciclib (Roscovitine) -- Second-Generation CDK Inhibitors -- Palbociclib (PD0332991) -- Ribociclib (LEE011) -- Abemaciclib (LY2835219) -- Dinaciclib (SCH727965) -- AT7519 -- BMS-387032 (SNS-032) -- Riviciclib -- Voruciclib (P1446A) -- CYC065 -- Toxicity of CDK Inhibitors -- Similarities and Differences Between CDK4 and 6 Inhibitors -- Reasons for the Failure of CDK Inhibitors -- Conclusion and Perspective -- Acknowledgments -- References -- Further Reading -- Chapter 10: Bcl-2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Introduction -- Bcl-2 Family Proteins -- Bcl-2 Homology Regions -- Structure and Interactions of Bcl-2 Family Proteins -- Structure -- Interaction Between Antiapoptotic and Proapoptotic Bcl-2 Proteins -- Bcl-2 Proteins Engaged in Apoptosis -- Two Major Apoptotic Pathways -- Roles of Bcl-2 Proteins in Apoptotic Pathway. , Rational for Bcl-2 Inhibitors as Sensitizing Agents -- Overexpression of Bcl-2 in Cancer Patients -- Mechanism of Overexpression of Bcl-2 in Cancers -- Bcl-2-Associated Resistance to Cancer Therapy -- Targeting Bcl-2 for Cancer Therapies Strategy -- Bcl-2 Antisense Oligonucleotide in Cancer Therapy -- Oblimersen (G3139, Genasense) -- Small Molecule Downregulating Gene or Protein Expression of Bcl-2 -- Histone Deacetylase Inhibitor (HDACI), sodium butyrate (NaB), Vorinostat, and Depsipeptide -- Synthetic Retinoid -- Cyclin-Dependent Kinase (CDK) Inhibitors -- BH3 Mimetics -- Levo gossypol (AT101, Ascenta) -- ABT-737(A-779024) and ABT-263 (Navitoclax) -- ABT-199 (Venetoclax) -- S55746 (Bcl201, Servier-1) -- Small Molecule to Targeting Other Antiapoptotic Proteins -- Selective Inhibitors Targeting Bcl-XL Agent, A-1155463, A-1331852, and WEHI-539 -- Selective Anti-Mcl-1 Agents, UMI-177, A-1210477, and AMG176 -- Conclusion -- Acknowledgment -- References -- Further Reading -- Chapter 11: Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors -- Introduction -- Interactions Between MDR-Linked ABC Transporters and PKIs -- Plk1 Inhibitors -- BI 2536 -- Volasertib (BI 6727) -- GSK461364 -- NMS-P937 -- BRAF Inhibitors -- Sorafenib (BAY43-9006) -- Vemurafenib (PLX4032) -- PLX4720 -- Dabrafenib (GSK2118436) -- CEP-32496 -- JAK Inhibitors -- WHI-P154 -- Ruxolitinib (INCB018424) -- Momelotinib (CYT387) -- CEP-33779 -- NVP-BSK805 -- Conclusion -- Acknowledgments -- References -- Further Reading -- Chapter 12: PI3K/AKT Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- The PI3K/AKT Pathway Overview -- The PI3K/Akt Pathway Involved in Diverse Resistances to Chemotherapy -- The PI3K/Akt Pathway Contributes to MDR -- The PI3K/AKT Pathway Contributes to Maintenance of Cancer Stem Cells. , The PI3K/Akt Pathway Contributes to the Resistance to Traditional Cytotoxic Chemotherapy -- The PI3K/AKT Pathway Contributes to the Resistance to RTK Inhibitors -- The PI3K/AKT Pathway Contributes to Resistance to Endocrine Therapy -- The PI3K/Akt Pathway Contributes to Resistance to the RAS/RAF/MAPK Pathway Inhibitors -- The PI3K/Akt Pathway Contributes to Resistance to the Hedgehog Pathway Inhibitors -- The PI3K/Akt Pathway Contributes to Resistance to Proteasome Inhibitors -- The PI3K/Akt Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Copanlisib -- Idelalisib -- ZSTK474 -- BKM120 -- GDC0941 -- NVP-BEZ235 -- Other PI3K Inhibitors -- AKT Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Perifosine -- MK2206 -- AZD5363 -- Conclusion -- Acknowledgments -- References -- Chapter 13: Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy -- Introduction -- Bortezomib Combination With Chemotherapy Drugs -- Combination in MM -- Combination in MCL -- Combination in Other Tumors -- Combination of Carfilzomib With Chemotherapeutic Drugs -- Combination of Marizomib With Chemotherapeutic Drugs -- Combination of Ixazomib With Chemotherapeutic Drugs -- Other Proteasome Inhibitors Combination With Chemotherapy Drugs -- Oprozomib, Delanzomib, and MLN-2238 -- Chloroquine -- MG132 -- Gambogic Acid -- Pristimerin -- Conclusions and Perspectives -- Acknowledgments -- References -- Chapter 14: Combining PI3K/Akt/mTOR Inhibition With Chemotherapy -- Introduction -- PI3K/Akt/mTOR Signaling -- Feedback Loops: S6K and PTEN -- PI3K/Akt/mTOR Pathway Activation and Chemotherapy Resistance -- PI3K/Akt/mTOR Inhibitors as Chemosensitizers -- Rapamycin and the Rapalogs -- PI3K Inhibitors -- Dual PI3K/mTOR Kinase Inhibitors -- Dual mTORC1/mTORC2 Inhibitors -- Akt Inhibitors -- Conclusion -- Acknowledgment -- References. , Chapter 15: MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy.

Additional Edition: ISBN 0-12-816435-2

Language: English

UID:

Format: 1 Online-Ressource (285 p.)

ISBN: 9782889634989

Content: This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact

Note: English

Language: English

URL: kostenfrei

UID:

Format: 1 Online-Ressource (285 p.)

ISBN: 9782889638796

Content: This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact

Note: English

Language: English

URL: kostenfrei

UID:

Format: 1 Online-Ressource (366 p.)

ISBN: 9782889662753

Content: This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact

Note: English

Language: English

URL: kostenfrei

UID:

Format: 1 online resource (IX, 294 p.)

ISBN: 9783110756456

Series Statement: Symbolism : An International Annual of Critical Aesthetics ,

Content: Special Focus: Law and Literature This special focus issue of Symbolism takes a look at the theoretical equation of law and literature and its inherent symbolic dimension. The authors all approach the subject from the perspective of literary and book studies, foregrounding literature’s potential to act as supplementary to a very wide variety of laws spread over historical, geographical, cultural and spatial grounds. The theoretical ground laid here thus posits both literature and law in the narrow sense. The articles gathered in this special issue analyse Anglophone literatures from the Renaissance to the present day and cover the three major genres, narrative, drama and poetry. The contributions address questions of the law’s psychoanalytic subconscious, copyright and censorship, literary negotiations of colonial and post-colonial territorial laws, the European ‘refugee debate’ and migration narratives, fictional debates on climate change, contemporary feminist drama and classic 19th-century legal narratives. This volume includes two insightful analyses of poetic texts with a special focus on the fact that poetry has often been neglected within the field of law and literature research. Special Focus editor: Franziska Quabeck, Westfälische Wilhelms-Universität Münster, Germany.

Note: Frontmatter -- , Foreword from the Editors -- , Contents -- , Special Focus: Law and Literature -- , Introduction: Symbolism, Law and Literature -- , Reading the Unconscious of the Law: From Psychoanalytical Legal Theory to Early Modern Law and Literature -- , Contracts, Clauses, Controversy: John Hersey, Alfred A. Knopf, Inc. and Reader’s Digest Condensed Books -- , Decadent Echoes, the Language of Censorship and Radclyffe Hall’s The Well of Loneliness -- , “Stay on Country”: The Indigenous Australian Challenge to White Property, Terra Nullius, and Native Title in Tara June Winch’s The Yield -- , Legal and Poetic Figurations of Wholeness in from unincorporated territory and the Insular Cases -- , ‘the real feel of hard time’: Lyrico-Carceral Temporalities in C.D. Wright’s One Big Self: An Investigation (2007) -- , “I Have Shown You Milk”: Performing Legal Truths in Nina Raine’s Consent and Lucy Kirkwood’s The Welkin -- , Law on Ice: Polarizing Legal Expertise in Popular Climate Change Fiction -- , The Fiction of Justice: Human Smuggling in European Law and Middle Eastern Refugee Narratives -- , In Defense of Mr Micawber: Symbolic Equity in Dickens -- , General Section -- , Tolkien’s Dragons: Sources, Symbols, and Significance -- , Suspending the Assemblage: Todd Haynes’ Safe (1995) and the Return of the Self -- , Book Reviews -- , Stephanie Elsky. Custom, Common Law, and the Constitution of English Renaissance Literature -- , Siobhan Somerville, Ed. The Cambridge Companion to Queer Studies -- , Shazia Rahman. Place and Postcolonial Ecofeminism: Pakistani Women’s Literary and Cinematic Fictions -- , Amy Cook. Shakespearean Futures: Casting the Bodies of Tomorrow on Shakespeare’s Stages Today -- , Marisa Palacios Knox. Victorian Women and Wayward Reading: Crises of Identification -- , List of Contributors -- , Index , In English.

Additional Edition: ISBN 9783110756531

Additional Edition: ISBN 9783110756395

Language: English

DOI: 10.1515/9783110756456

URL: https://doi.org/10.1515/9783110756456

URL: https://www.degruyter.com/isbn/9783110756456

URL: https://doi.org/10.1515/9783110756456

URL: https://www.degruyter.com/isbn/9783110756456

URL: lizenzpflichtig

URL: lizenzpflichtig

URL: Cover